Technology Appraisal Committee Meeting (Committee C)

Minutes: Confirmed

Date and Time: Wednesday 12 July 2017, 10:00 to 15:00

Venue: National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

Present:
1. Chair Professor Andrew Stevens  Present for all notes
2. Professor Kathryn Abel  Present for all notes
3. Mr Kamal Balakrishnan  Present for all notes
4. Mr David Chandler  Present for all notes
5. Dr Prithviraj Das  Present for all notes
6. Mr John P Hampson  Present for all notes
7. Dr Nigel Langford  Present for all notes
8. Dr Iain Miller  Present for all notes
9. Paul Robinson (committee A)  Present for all notes
10. Professor Stephen O’Brien  Present for all notes
11. Professor Peter Selby  Present for all notes
12. Professor Matt Stevenson  Present for all notes
13. Dr Paul Tappenden  Present for all notes
14. Dr Judith Wardle  Present for all notes

In attendance:

Meindert Boysen  Programme Director, National Institute for Health and Care Excellence  Present for all notes
Frances Sutcliffe  Associate Director, National Institute for Health and Care Excellence  Present for all notes
Stephanie Yates  Project Manager, National Institute for Health and Care Excellence  Present for all notes
Mandy Tonkinson  Administrator, National Institute for Health and Care Excellence  Present for all notes
Marcela Haasova  Technical Analyst,  Present for notes 5 to 15
Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia and brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma.

2. The Chair informed the Committee of the non-public observers at this meeting: Christopher Eatough and Leslie Hayes.

3. Apologies were received from Mr Michael Chambers, Mrs Gail Coster, Professor Andrew Renehan and Dr Robert Walton.

Any other business

4. None

Appraisal of inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia [ID893]

Part 1 – Open session
5. The Chair welcomed the invited experts: Peter Clark, Edward Cox and Susan Griffin to the meeting and they introduced themselves to the Committee.

6. The Chair welcomed company representatives from Pfizer to the meeting.

7. The Chair asked all Committee members to declare any relevant interests

7.1. Professor Andrew Stevens, Professor Kathryn Abel, Mr Kamal Balakrishnan, Mr David Chandler, Dr Prithviraj Das, Mr John P Hampson, Dr Nigel Langford, Dr Iain Miller, Paul Robinson, Dr Peter Selby, Professor Matt Stevenson, Dr Paul Tappenden and Dr Judith Wardle all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia.

7.2. Professor Stephen O’Brien declared a personal non-specific financial interest as his University and/or NHS Trust has received research funding for clinical trial work from the following companies: Pfizer, Novartis and Bristol-Myers Squibb.

7.2.1. It was agreed that this declaration would not prevent Professor Stephen O’Brien from participating in this section of the meeting.

7.3. The Chair asked all NICE Staff to declare any relevant interests.

7.4. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia.

8. The Chair asked all other invited guests (ERG and invited experts, not including observers) to declare their relevant interests.

8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia.

9. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

10. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

11. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings)
Act 1960)" and all public attendees left the meeting.

12. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

13. Discussion on confidential information continued. This information was supplied by the company.

14. The Committee continued to discuss the clinical and cost effectiveness of inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia.

14.1. The committee decision was based on consensus.

15. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Appraisal of brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma [ID512]

Part 1 – Open session

16. The Chair welcomed the invited experts: Dwayne Boyers, Peter Clark and Graham Scotland to the meeting and they introduced themselves to the Committee.

17. The Chair welcomed company representatives from Takeda UK to the meeting.

18. The Chair asked all Committee members to declare any relevant interests

18.1. Professor Andrew Stevens, Professor Kathryn Abel, Mr Kamal Balakrishnan, Mr David Chandler, Dr Prithviraj Das, Mr John P Hampson, Dr Nigel Langford, Dr Iain Miller, Paul Robinson, Dr Peter Selby, Professor Matt Stevenson, Dr Paul Tappenden, Dr Judith Wardle all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma.

18.2. Professor Stephen O’Brien declared a personal non-specific financial interest as his university had previously received research funding for clinical trials from Ariad which was taken over by Takeda UK in February 2017.

18.2.1. It was agreed that this declaration would not prevent Professor Stephen O’Brien from participating in this section of the meeting.

19. The Chair asked all NICE Staff to declare any relevant interests.

19.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma.
20. The Chair asked all other invited guests (ERG and invited experts, not including observers) to declare their relevant interests.

20.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma.

21. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

22. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

23. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

24. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

25. Discussion on confidential information continued. This information was supplied by the company.

26. The Committee continued to discuss the clinical and cost effectiveness of brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma.

26.1. The committee decision was based on consensus.

27. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Date, time and venue of the next meeting

28. Tuesday 15 August 2017 at Holiday Inn Manchester City Centre, 25 Aytoun St, Manchester, M1 3AE.